High dose daunorubicin: New standard of care for FLT3 ITD mutant AML

Leuk Res. 2018 Jun:69:87-88. doi: 10.1016/j.leukres.2018.04.011. Epub 2018 Apr 23.

Authors

Eunice S Wang¹, Kristen O'Dwyer²

Affiliations

¹ Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States. Electronic address: eunice.wang@roswellpark.org.
² Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States.

PMID: 29705536
DOI: 10.1016/j.leukres.2018.04.011

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anthracyclines
Daunorubicin*
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute*
Standard of Care
fms-Like Tyrosine Kinase 3

Substances

Anthracyclines
FLT3 protein, human
fms-Like Tyrosine Kinase 3
Daunorubicin